Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is well-positioned for future growth as it anticipates securing additional human licensing deals in 2026, which could significantly enhance topline revenue. The company offers a unique approach in the liquid biopsy market by focusing on circulating cell-free nucleoproteins, and recent validation studies suggest promising early-stage detection capabilities, especially in colorectal and lung cancers. Furthermore, the combination of rigorous validation from reputable institutions and advanced technology for high-purity circulating tumor DNA datasets supports VolitionRX's competitive edge, potentially increasing clinical adoption and establishing new revenue streams in diagnostics.

Bears say

VolitionRX Ltd faces several critical threats that contribute to a negative outlook on its stock, including potential failures in clinical development of its diagnostic products and challenges in securing necessary license agreements. Additionally, the company reported a notable net loss of $23.4 million, translating to a loss of $0.22 per share, indicating financial strain that could hinder its operations. The persistent issues related to achieving market traction for its products, compounded by risks of dilution and potential delisting, further raise concerns regarding the viability of its business model.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.